
LIB Therapeutics Announces Key Results from Presentations at 2025 European Atherosclerosis Society Meeting in Glasgow May 5-6
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep (LeroChol ®), a novel, monthly, small dose third-generation PCSK9 inhibitor today announced results presented at the May 5-7 2025 European Atherosclerosis Society meeting in Glasgow.
LERODALCIBEP ADJUDICATED CARDIOVASCULAR EVENTS IN A PRE-DEFINED POOLED ANALYSIS OF THREE LARGE LONG TERM PHASE III STUDIES – Dr David Kallend May 5th
As part of the safety analysis, a prespecified exploratory endpoint of major adverse cardiovasular events (MACE) adjudicated by a blinded Clinical Events Committee of all serious CV adverse events.
A patient-level, pre-defined pooled analysis of the pivotal placebo-controlled Phase III studies (LIBerate-HR, LIBerate-CVD and LIBerate-HeFH), included patients on maximally tolerated statin with or without other oral lipid-lowering-therapy.
Patients were randomized 2:1 to 300mg lerodalcibep or placebo monthly SC for 24 (LIBerate-HeFH) or 52 weeks (LIBerate-HR and LIBerate-CVD).
*placebo adjusted mITT analysis; # MACE = composite of death, resuscitated cardiac arrest, acute myocardial infarction (STEMI and NSTEMI), hospitalization for unstable angina, stroke and coronary revascularization
The early and large risk reductions in MACE of 45% to 50% provide encouraging insights into the potential CV benefits of lowering LDL-C with lerodalcibep and these findings await confirmation in a planned large definitive CV outcomes trial to start Q3 this year.
PHASE 3 POOLED LONG-TERM SAFETY AND EFFICACY OF LERODALCIBEP IN PATIENTS WITH ASCVD, HEFH, VERY HIGH OR HIGH RISK FOR ASCVD – David Kallend May 6
Pooled safety and efficacy was assessed from the key three blinded placebo-controlled Phase 3 trials (LIBerate-CVD, LIBerate-HR and LIBerate-HeFH) in patients with atherosclerotic cardiovascular disease (ASCVD), very high or high risk for ASCVD on stable maximally tolerated statin therapy and additional oral agents.
The mean (SE) placebo-adjusted reductions in LDL-C at (Weeks 24 and 52 respectively) 'trough' with lerodalcibep were;
mITT analysis was, 58.6(1.3)% and 59.0(1.5)%,
ITT with imputation was 54.9(1.4)% and 52.3(1.7)%
Per-Protocol analysis was 61.8(1.4)% and 62.3(1.5)%
The placebo adjusted LDL-C reduction at 'peak' (2 week post dose) in the mITT population was 73.7% at Week 50 and the mean of weeks 50 and 52 was 66.0(1.3)%.
On lerodalcibep, 83% of subjects at Week 24 and 90% of subjects at Week 52 achieved both ESC/EAS recommended targets of >50 additional LDL-C reduction and their new lower targets.
Lerodalcibep was well tolerated with 90.3% and 88.7% of subjects completing the study at Weeks 24 and 52 respectively
Adverse events were similar between groups, other than more mild injection site reactions (ISRs) on lerodalcibep. The few and sporadic in-vitro anti-drug antibodies had no impact on efficacy or safety.
'We are very pleased and encouraged by the results from the pooled key registration trials, which were large, of long duration, and placebo-controlled,' said Dr. David Kallend, Chief Medical Officer of LIB Therapeutics. 'The data demonstrates substantial and durable reductions in LDL-C - both in absolute terms and percentage change - as well as in other atherogenic lipoproteins such as Lp(a) and ApoB.'
He continued, 'Lerodalcibep was well tolerated with no safety concerns or drug-drug interactions, especially important for patients with CVD already on multiple other oral therapeutic agents. Its patient-friendly profile, including the only monthly, 12 doses per year, single small-volume SC injection which along with long-term ambient stability not requiring refrigeration by patients, makes it especially well-suited for patients with CVD or at high-risk for CVD, including those with FH, to help them achieve the new, more aggressive LDL-C targets and maintain life long adherence to therapy.'
'While the number of CV events in the pooled phase trials was limited, the early, large, and statistically significant reductions in MACE are highly encouraging. We look forward to initiating a differentiated cardiovascular outcomes trial to further explore and confirm these findings.'
About Lerodalcibep
Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. The anti-PCSK9 binding domain of Lerodalcibep is an 11-kDa polypeptide called an adnectin, engineered for high-affinity subnanomolar binding to human PCSK9 and fused to human serum albumin to enhance plasma half-life.
In clinical trials, Lerodalcibep has demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and ≥50% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations, and is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH.
The global Phase 3 LIBerate program enrolled a diverse population of over 2,900 patients with CVD, without CVD at very high and high risk for CVD, including heterozygous and homozygous familial hypercholesterolemia. Lerodalcibep was dosed once monthly for up to 52 weeks in these key registration-enabling, placebo-controlled trials, and over 2,400 patients have continued in the 72-week open-label extension trial. Following the FDA BLA submission, LIB is preparing a Marketing Authorization Application to the European Medicines Agency.
LIB submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in December 2024, and received formal filing by FDA in February with and anticipated PDUFA date in mid Dec this year. LIB is seeking approval of lerodalcibep to reduce LDL-C for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidemia, including heterozygous and homozygous familial hypercholesterolemia (HeFH / HoFH).
About LIB Therapeutics Inc.
LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing Lerodalcibep to the millions of patients with cardiovascular disease and to the 30 million individuals with familial hypercholesterolemia (FH) around the world, who require additional large reductions in LDL-C, despite maximally tolerated statins and other lipid lowering agents, to achieve LDL-C goals.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Align Managed Services Wins Best Cyber Resilience Solution in the 2025 FTF News Technology Innovation Awards
NEW YORK, June 09, 2025--(BUSINESS WIRE)--Align, the premier global provider of technology infrastructure solutions and Managed IT Services, announces today that Financial Technologies Forum (FTF) News has awarded its Align Guardian Managed Detection and Response (MDR) Solution the Best Cyber Resilience Solution award in the 2025 FTF News Technology Innovation Awards. The awards celebrate and recognize the professionals, financial technology vendors, service providers, industry bodies, and regulators who have made significant strides and noteworthy achievements in operational excellence over the 2024 calendar year. Align Managed Services offers a comprehensive Managed IT Services Stack with built in cybersecurity solutions focused on the financial services and alternative investment community. Its Cybersecurity offering is designed to address the evolving threat landscape and meet the stringent compliance requirements in the financial services industry. This includes Align Guardian, a Next-Generation Managed Detection and Response (MDR) tool powered by Adlumin (an N-able company), that keeps organizations safe from constantly evolving cyber-attacks that traditional security defenses simply cannot detect. With 24x7x365 monitoring by Security Operations Center (SOC) protecting against known and unknown threats in real time, Align's clients are protected by continuous hunting, detection, and response to threats. Cybersecurity is a core priority for us, and we're honored to be recognized by FTF News," said Vinod Paul, President of Align Managed Services. "Our goal is to deliver robust, evolving cybersecurity solutions so our clients can focus fully on growing their business — without distraction or concern over data security. As the regulatory landscape tightens and cyber threats become more sophisticated, we remain committed to staying ahead, adapting in step with our clients and the industry to provide the protection and peace of mind they need to succeed." In 2024, Align added two major improvements to its Align Guardian solution targeted at ransomware prevention, and exfiltration detection and response. The innovative ransomware detection solution is designed to detect and halt ransomware in its tracks, safeguarding files from encryption and providing organizations with the peace of mind to focus on their core business operations. The cutting-edge exfiltration prevention feature is designed to quickly detect and stop attackers from exfiltrating data, providing a defense against modern ransomware tactics that employ double-extortion techniques. To learn more about Align Cybersecurity, visit To learn more about Align Managed Services, visit About Align Align is a premier global provider of technology infrastructure solutions. For over 38 years, leading firms worldwide have relied on Align to guide them through IT challenges, delivering complete, secure solutions for business change and growth. Align is headquartered in Dallas, Texas and has offices in New York City, London, Chicago, San Francisco, Arizona, New Jersey, Texas and Virginia. To learn more about Align Managed Services, visit our website here: and follow Align on LinkedIn and at @AlignITAdvisor on X. View source version on Contacts Ashley Holbrookaholbrook@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
KBRA Assigns Preliminary Ratings to WBHT 2025-WBM
NEW YORK, June 09, 2025--(BUSINESS WIRE)--KBRA announces the assignment of preliminary ratings to six classes of WBHT 2025-WBM, a CMBS single-borrower securitization. The collateral for the transaction is a $340.0 million non-recourse, first lien mortgage loan that is expected to be co-originated by Wells Fargo Bank, National Association and Goldman Sachs Bank USA. The floating rate loan is expected to have a two-year initial term with three 12-month extension options and require monthly interest-only payments. The mortgage loan will be secured by the borrower's leasehold interests in the Waikiki Beach Marriott located in Honolulu, Hawaii. The subject property features 1,307 keys, 10 food & beverage outlets, 24,572 sf of indoor meeting and ballroom space, 54,287 sf of retail space, two outdoor pools, a full-service spa, a fitness facility, game room, and a business center. The hotel was constructed between 1971 and 1979. Since 2017, the sponsor has invested approximately $118.4 million ($90,572 per key) on capital improvements at the property. The most recent comprehensive renovation was largely completed in 2022 when the sponsor spent $95.2 million ($72,863 per key) to renovate all guestrooms, the third floor terrace and pool deck as well as construct the Luana Lounge to cater to Japanese tour groups. For the TTM 3/2025 period, the subject property achieved an occupancy of 83.6% with an ADR of $262.96, resulting in a RevPAR of $219.87. As of the TTM 3/2025 period, the property achieved occupancy, ADR and RevPAR penetration rates of 98.0%, 102.6% and 100.5%, respectively. KBRA's analysis of the transaction included a detailed evaluation of the property's cash flows using our North American CMBS Property Evaluation Methodology, and the application of our North American CMBS Single Borrower & Large Loan Rating Methodology. In addition, KBRA also relied on its Global Structured Finance Counterparty Methodology for assessing counterparty risk in this transaction, and its ESG Global Rating Methodology, to the extent deemed applicable. The results of our analysis yielded a KBRA net cash flow (KNCF) for the subject of approximately $28.8 million, which is 22.3% below the issuer's NCF, and a KBRA value of approximately $288.4 million, which is 59.3% below the appraiser's as-is value. The resulting in-trust KBRA Loan to Value (KLTV) is 117.9%. In our analysis of the transaction, we also reviewed and considered third party engineering, environmental, and appraisal reports, the results of our site inspection of the property, and legal documentation review. To access ratings and relevant documents, click here. Click here to view the report. Methodologies CMBS: North American CMBS Property Evaluation Methodology CMBS: North American CMBS Single Borrower & Large Loan Rating Methodology Structured Finance: Global Structured Finance Counterparty Methodology ESG Global Rating Methodology Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009834 View source version on Contacts Analytical Contacts Laura Wolinsky, Senior Director (Lead Analyst)+1 Michael Brown, Managing Director+1 Nitin Bhasin, Senior Managing Director, Global Head of CMBS (Rating Committee Chair)+1 Business Development Contact Daniel Stallone, Managing Director+1 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤


Business Wire
17 minutes ago
- Business Wire
KBRA Assigns Preliminary Ratings to WBHT 2025-WBM
NEW YORK--(BUSINESS WIRE)--KBRA announces the assignment of preliminary ratings to six classes of WBHT 2025-WBM, a CMBS single-borrower securitization. The collateral for the transaction is a $340.0 million non-recourse, first lien mortgage loan that is expected to be co-originated by Wells Fargo Bank, National Association and Goldman Sachs Bank USA. The floating rate loan is expected to have a two-year initial term with three 12-month extension options and require monthly interest-only payments. The mortgage loan will be secured by the borrower's leasehold interests in the Waikiki Beach Marriott located in Honolulu, Hawaii. The subject property features 1,307 keys, 10 food & beverage outlets, 24,572 sf of indoor meeting and ballroom space, 54,287 sf of retail space, two outdoor pools, a full-service spa, a fitness facility, game room, and a business center. The hotel was constructed between 1971 and 1979. Since 2017, the sponsor has invested approximately $118.4 million ($90,572 per key) on capital improvements at the property. The most recent comprehensive renovation was largely completed in 2022 when the sponsor spent $95.2 million ($72,863 per key) to renovate all guestrooms, the third floor terrace and pool deck as well as construct the Luana Lounge to cater to Japanese tour groups. For the TTM 3/2025 period, the subject property achieved an occupancy of 83.6% with an ADR of $262.96, resulting in a RevPAR of $219.87. As of the TTM 3/2025 period, the property achieved occupancy, ADR and RevPAR penetration rates of 98.0%, 102.6% and 100.5%, respectively. KBRA's analysis of the transaction included a detailed evaluation of the property's cash flows using our North American CMBS Property Evaluation Methodology, and the application of our North American CMBS Single Borrower & Large Loan Rating Methodology. In addition, KBRA also relied on its Global Structured Finance Counterparty Methodology for assessing counterparty risk in this transaction, and its ESG Global Rating Methodology, to the extent deemed applicable. The results of our analysis yielded a KBRA net cash flow (KNCF) for the subject of approximately $28.8 million, which is 22.3% below the issuer's NCF, and a KBRA value of approximately $288.4 million, which is 59.3% below the appraiser's as-is value. The resulting in-trust KBRA Loan to Value (KLTV) is 117.9%. In our analysis of the transaction, we also reviewed and considered third party engineering, environmental, and appraisal reports, the results of our site inspection of the property, and legal documentation review. To access ratings and relevant documents, click here. Click here to view the report. Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009834